Filing Flows › Journey Medical (DERM) › Q1 2026 › vs Q1 2025
Journey Medical (DERM) Q1 2026 vs Q1 2025 (year over year)
Journey Medical's revenue rose $2.8M (+21%) from $13.1M in Q1 2025 to $16.0M in Q1 2026. The biggest changes: Emrosi +$4.2M (+202%); Foam franchise products (Amzeeq & Zilxi) −$476K (-31%); Other / legacy −$450K (-62%).
Journey Medical, Q1 2026: revenue $16.0M (+22% year over year), operating margin -9.3%, net loss $2.2M, operating cash flow $2.9M. The chart draws each line against Q1 2025, the increases inside each band.
Every line
| Line | Q1 2026 | Q1 2025 | Change | % |
|---|---|---|---|---|
| Emrosi | $6.3M | $2.1M | $4.2M | +202% |
| Qbrexza | $5.0M | $5.2M | −$133K | -3% |
| Accutane | $3.3M | $3.7M | −$341K | -9% |
| Foam franchise products (Amzeeq & Zilxi) | $1.1M | $1.5M | −$476K | -31% |
| Other / legacy | $277K | $727K | −$450K | -62% |
| Revenue | $16.0M | $13.1M | $2.8M | +21% |
| Net loss | $2.2M | $4.1M | −$1.8M | -45% |
| Costs & expenses | $18.2M | $17.2M | $979K | +6% |
| Operating costs | $17.5M | $16.5M | $990K | +6% |
| Interest & other, net | $738K | $749K | −$11K | -1% |
| Cost of revenue | $6.2M | $4.8M | $1.4M | +30% |
| SG&A | $10.1M | $10.6M | −$460K | -4% |
| Other operating costs | $1.1M | $1.1M | $61K | +6% |
| Operating cash sources | $5.1M | $1.2M | $3.9M | +314% |
| Share-based compensation | $989K | $1.3M | −$334K | -25% |
| Working capital & other | $4.2M | −$82K | $4.2M | — |
| Net loss absorbed | $2.2M | $4.1M | −$1.8M | -45% |
| Operating cash flow | $2.9M | −$2.8M | $5.7M | — |
Questions
How much did Journey Medical's revenue grow year over year in Q1 2026?
Journey Medical's revenue rose $2.8M (+21%) from $13.1M in Q1 2025 to $16.0M in Q1 2026.
What drove Journey Medical's revenue change in Q1 2026?
Emrosi +$4.2M (+202%); Foam franchise products (Amzeeq & Zilxi) −$476K (-31%); Other / legacy −$450K (-62%).